Indoco Remedies Ltd

Meeting Details

• Board meeting scheduled for Tuesday, 27 October 2026.
• Time not disclosed.
• Location not disclosed.

Key Agenda Items

• Un-audited standalone and consolidated results for quarter and half-year ended 30 September 2026 to be considered and approved.

Other Notes

• Trading window remains closed for designated persons till 29 October 2026.

Regulatory update for physical shareholders

• SEBI circular requires PAN, KYC, mobile, signature, and bank details for physical holders.
• Dividends for physical folios will be paid electronically from April 1, 2024.
• Transfer of physical shares is not permitted since April 1, 2019.
• MUFG Intime India Private Limited is the RTA for updating details.
• Forms ISR-1, ISR-2, ISR-3, SH13, SH14 are available on the MUFG site.
• Email registration is optional but enables online services and nominations.
• Current folio statuses are provided for reference and to enable compliance.
• Dematerialisation process steps include opening a demat account and engaging a DP.
• RTA contact details and investor helpdesk are provided for queries.

Physical-shareholder KYC update

• SEBI circular requires physical-holding shareholders to furnish PAN, KYC, mobile, signature, and bank details.
• MUFG Intime India Private Limited is the RTA managing updates; forms are on their site.
• Dividends to be paid electronically per SEBI LODR Fifth Amendment Regulations 2025.
• Transfer of physical shares prohibited since 2019; dematerialisation encouraged.

WLPL incorporation

• Target: Warren Lifesciences Private Limited (WLPL), a newly incorporated Indian pharmaceutical entity.
• Authorized share capital Rs 1,00,000; 10,000 equity shares of Rs 10 each.
• Indoco to hold 100% of WLPL's paid-up capital.
• Cash consideration for 10,000 WLPL shares at Rs 10 each.
• Incorporated in India on 26 September 2026; yet to commence business.
• WLPL will manufacture, develop, and sell APIs, finished formulations, and key starting materials.
• WLPL is a wholly owned subsidiary and related party of Indoco Remedies Limited.
• Background: India-incorporated WLPL, registered in Mumbai; hasn't commenced business; no turnover history yet.
• Industry: pharmaceutical sector.

Target overview

• Warren Lifesciences Private Limited (WLPL) is the target entity in pharma, India.
• WLPL authorised capital Rs 1,00,000; 10,000 shares of Rs 10 each.

Ownership and related party

• WLPL is a wholly owned subsidiary; Indoco holds 100% stake.
• WLPL is a related party of Indoco Remedies.

Purpose and business

• Object to manufacture, develop, sell APIs, formulations, and key starting materials.

Regulatory and approvals

• No approvals required for incorporation.

Financials and consideration

• Cost of acquisition: Rs 1,00,000; cash consideration for 100% stake.
• 10,000 WLPL equity shares subscribed at Rs 10 per share.

Background and timeline

• WLPL incorporated in India on 26 September 2026; yet to commence business.
• Indoco to subscribe for 100% of WLPL's paid-up capital.

Indoco Remedies Ltd: Trading Window closed from 1 October 2026 until 48 hours after declaration of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30 September 2026.

Target overview

• Target: Warren Lifesciences Private Limited to be incorporated as a wholly owned subsidiary of Indoco Remedies.
• Industry: Pharmaceutical sector; India-based operations.
• Purpose: Manufacture, develop, and sell APIs, finished formulations, and key starting materials.
• Capital: Authorized Rs 100,000; paid-up Rs 100,000; 10,000 shares of Rs 10 each.
• Shareholding: Indoco to hold 100% equity in Warren Lifesciences Private Limited.
• Consideration: Cash for subscribing to equity shares.
• Price: Rs 10 per share (face value).
• Regulatory: ROC/MCA approvals and other regulatory clearances.
• Timeline: Incorporation to be completed in due course; date to be intimated.
• Background: Pharma product manufacturing focus; incorporation pending.
• Status: 100% ownership by Indoco; no external promoter stake.
• Turnover: Not disclosed.

Subsidiary formation

• Target: Warren Lifesciences Private Limited, to be incorporated in India as a wholly owned subsidiary.
• Industry: Pharmaceutical sector; products include APIs, finished formulations, and key starting materials.
• Funding: Cash consideration; shares subscribed at face value of Rs 10 per share.
• Capital structure: Authorized and paid-up capital of Rs 1,00,000 comprising 10,000 equity shares.
• Shareholding: Indoco Remedies Limited will hold 100% of Warren Lifesciences.
• Regulatory approvals: Incorporation subject to ROC/MCA and other statutory approvals.
• Timeline: Date of incorporation will be intimated; no completion date specified.
• Purpose: Expand pharmaceutical manufacturing capabilities within the group.
• Background: Proposed company yet to be incorporated, India-based focus on APIs and formulations.

AGM details

• AGM held on 17 September 2026 at 10:30 IST via VC/OAVM.
• Remote e-voting window: 13–16 September 2026; cut-off date 10 September 2026.

Key resolutions and results

• Item 1 (Ordinary): Standalone financials adopted; 99.99% in favour; passed.
• Item 2 (Ordinary): Consolidated financials adopted; 100% in favour; passed.
• Item 3 (Ordinary): Final dividend of ₹0.20 per share; 99.94% in favour; passed.
• Item 4 (Ordinary): Re-appointment of Aditi Panandikar by rotation; 99.94% in favour; passed.
• Item 5 (Ordinary): Cost Auditors remuneration for FY 2026-27 ratified; 100% in favour; passed.
• Item 6 (Special): Re-appoint Aditi Panandikar as Managing Director; 85.73% in favour; passed.
• Item 7 (Special): Continuation of Vasudha Kamath as NED post-75 years; 94.37% in favour; passed.
• Item 8 (Special): Borrowing limits increased; 99.96% in favour; passed.
• Item 9 (Special): Sell/charge on assets; 99.44% in favour; passed.

Dividend

• Final dividend approved: ₹0.20 per equity share.

Directors & management changes

• Re-appointment of Aditi Panandikar as Director by rotation; approved.
• Re-appointment of Aditi Panandikar as Managing Director; approved.

Auditors and remuneration

• Remuneration of Cost Auditors for FY 2026-27 ratified.

Financing and asset encumbrance

• Borrowing limits increased under Section 180(1)(c); approved.
• Approval to create mortgage or charge on assets; approved.